Table of Contents Author Guidelines Submit a Manuscript
Critical Care Research and Practice
Volume 2016, Article ID 1245815, 7 pages
http://dx.doi.org/10.1155/2016/1245815
Clinical Study

Achievement of Vancomycin Therapeutic Goals in Critically Ill Patients: Early Individualization May Be Beneficial

1Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14155/6451, Iran
2Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan 71746-73461, Iran
3Anesthesiology and Intensive Care Department, School of Medicine, Tehran University of Medical Sciences, Tehran 14155/6451, Iran
4Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14155/6451, Iran
5Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran 14155/6451, Iran

Received 3 November 2015; Revised 20 January 2016; Accepted 16 February 2016

Academic Editor: Timothy E. Albertson

Copyright © 2016 Bita Shahrami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. P. Dellinger, M. M. Levy, A. Rhodes et al., “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012,” Critical Care Medicine, vol. 41, no. 2, pp. 580–637, 2013. View at Google Scholar
  2. D. F. Gaieski, M. E. Mikkelsen, R. A. Band et al., “Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department,” Critical Care Medicine, vol. 38, no. 4, pp. 1045–1053, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. National Nosocomial Infections Surveillance System, “National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004,” American Journal of Infection Control, vol. 32, no. 8, pp. 470–485, 2004. View at Publisher · View at Google Scholar
  4. L. B. Rice, “Antimicrobial resistance in gram-positive bacteria,” American Journal of Infection Control, vol. 119, no. 6, pp. S11–S19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. E. W. Hancock, “Mechanisms of action of newer antibiotics for Gram-positive pathogens,” Lancet Infectious Diseases, vol. 5, no. 4, pp. 209–218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. C. Moellering Jr., “Vancomycin: a 50-year reassessment,” Clinical Infectious Diseases, vol. 42, supplement 1, pp. S3–S4, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. S. K. Fridkin, J. C. Hageman, M. Morrison et al., “Methicillin-resistant Staphylococcus aureus disease in three communities,” The New England Journal of Medicine, vol. 352, no. 14, pp. 1436–1444, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. L. L. G. Miller, F. Perdreau-Remington, G. Rieg et al., “Necrotizing fasciitis caused by community-associated methicillin-resistant: Staphylococcus aureus in Los Angeles,” The New England Journal of Medicine, vol. 352, no. 14, pp. 1445–1453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. R. McDonald, N. D. Friedman, J. E. Stout, D. J. Sexton, and K. S. Kaye, “Risk factors for ineffective therapy in patients with bloodstream infection,” Archives of Internal Medicine, vol. 165, no. 3, pp. 308–313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Roberts and J. Lipman, “Pharmacokinetic issues for antibiotics in the critically ill patient,” Critical Care Medicine, vol. 37, no. 3, pp. 840–851, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. G. S. Gous, M. D. Dance, J. Lipman, D. K. Luyt, R. Mathivha, and J. Scribante, “Changes in vancomycin pharmacokinetics in critically ill infants,” Anaesthesia and Intensive Care, vol. 23, no. 6, pp. 678–682, 1995. View at Google Scholar · View at Scopus
  12. F. Pea, L. Porreca, M. Bàraldo, and M. Furlanut, “High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 3, pp. 329–335, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. C. A. DeRyke and D. P. Alexander, “Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration,” Hospital Pharmacy, vol. 44, no. 9, pp. 751–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Rybak, B. Lomaestro, J. C. Rotschafer et al., “Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,” American Journal of Health-System Pharmacy, vol. 66, no. 1, pp. 82–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Venkataraman and J. A. Kellum, “Defining acute renal failure: the RIFLE criteria,” Journal of Intensive Care Medicine, vol. 22, no. 4, pp. 187–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. G. Hall II, C. A. Giuliano, K. K. Haase et al., “Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study,” BMC Infectious Diseases, vol. 12, article 104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Dersch-Mills, T. Bengry, A. Akierman, B. Alshaikh, and K. Yusuf, “Assessment of initial vancomycin dosing in neonates,” Paediatrics and Child Health, vol. 19, no. 6, pp. e30–e34, 2014. View at Google Scholar · View at Scopus
  18. L. K. Hidayat, D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer, “High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity,” Archives of Internal Medicine, vol. 166, no. 19, pp. 2138–2144, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. T. P. Lodise, B. Lomaestro, J. Graves, and G. L. Drusano, “Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1330–1336, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Liu, A. Bayer, S. E. Cosgrove et al., “Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children,” Clinical Infectious Diseases, vol. 52, no. 3, pp. e18–e55, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Crumby, E. Rinehart, M. C. Carby, D. Kuhl, and A. J. Talati, “Pharmacokinetic comparison of nomogram-based and individualized vancomycin regimens in neonates,” American Journal of Health-System Pharmacy, vol. 66, no. 2, pp. 149–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Patel, M. P. Pai, K. A. Rodvold, B. Lomaestro, G. L. Drusano, and T. P. Lodise, “Vancomycin: we can't get there from here,” Clinical Infectious Diseases, vol. 52, no. 8, pp. 969–974, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. N. Neely, G. Youn, B. Jones et al., “Are vancomycin trough concentrations adequate for optimal dosing?” Antimicrobial Agents and Chemotherapy, vol. 58, no. 1, pp. 309–316, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. M. P. Pai, M. Neely, K. A. Rodvold, and T. P. Lodise, “Innovative approaches to optimizing the delivery of vancomycin in individual patients,” Advanced Drug Delivery Reviews, vol. 77, pp. 50–57, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. T. G. Cantú, N. A. Yamanaka-Yuen, and P. S. Lietman, “Serum vancomycin concentrations: reappraisal of their clinical value,” Clinical Infectious Diseases, vol. 18, no. 4, pp. 533–543, 1994. View at Google Scholar · View at Scopus
  26. T. P. Lodise, J. Graves, A. Evans et al., “Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3315–3320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. The European Committee on Antimicrobial Susceptibility Testing, “Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1,” 2013, http://www.eucast.org/.
  28. The European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016, http://www.eucast.org.
  29. A. A. Mangoni and S. H. D. Jackson, “Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications,” British Journal of Clinical Pharmacology, vol. 57, no. 1, pp. 6–14, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Turnheim, “When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly,” Experimental Gerontology, vol. 38, no. 8, pp. 843–853, 2003. View at Publisher · View at Google Scholar · View at Scopus